Sign in
KMSTF Stock Price, Chart, Stats & News
Kadimastem Ltd
Save
Kadimastem Ltd (KMSTF) does not currently pay a dividend.
9.50M
Market cap
–
Current P/E
–
Forward P/E
KMSTF chart
1M
3M
1Y
5Y
Loading chart...
About
Health care
Sector
Biotechnology
Industry
Kadimastem Ltd, an Israeli biopharmaceutical company, focuses on pioneering regenerative medicine therapies that utilize cells originating from human embryonic stem cells, primarily targeting neurodegenerative disorders. Its developmental pipeline features AstroRx, a clinical-grade human astrocyte therapy presently undergoing Phase 1/2a clinical trials for amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions. Additionally, the company is developing IsletRx, a clinical-grade pancreatic islet cell therapy designed to treat diabetes.
Similar securities
Based on sector and market capitalization
Report issue